ABCL-325: Diffuse Large B-Cell Lymphoma of the Uterus: A SEER Database Analysis

Context: Extra-nodal diffuse large B-cell lymphoma (DLBCL) affecting the uterus is a rare entity. Most of the epidemiology and prognosis for uterine DLBCL is derived from case reports and series. Objective: Our main objective was to investigate the demographics, clinical characteristics, and survival of women with primary uterine DLBCL using a multi-institutional database. Design: We retrospectively queried for women with DLBCL of the uterus from the National Cancer Institute\u0027s Surveillance, Epidemiology, and End Results (SEER) database from 1975–2017. Setting: Public database. Patients or other participants: All women with diagnosis of DLBCL of uterus. Interventions: N/A Main outcome measures: Demographic, clinical characteristics, and survival of women with primary DLBCL of uterus. We also looked at survival difference in the rituximab era (before vs after 1997). Results: A total of 223 cases were identified in the database. The primary sites were cervix uteri NOS (56.1%), endometrium (17.9%), uterus NOS (17.0%), corpus uteri (6.3%), myometrium (1.8%), and isthmus uteri (1.9%). Most women were between 40–64 years (45.7%) and 35.4% were \u003e65 years. Uterine DLBCL patients tended to be younger compared to non-uterine DLBCL cases (P Conclusions: Uterine DLBCL is a rare presentation of DLBCL. The most common site of uterine DLBCL is cervix uteri. Most women affected are between 40–64 years of age. Survival in patients with uterine DLBCL was superior in comparison to patients with non-uterine DLBCL cases.